MT2A and melanoma: Immunoblot blot analysis revealed that MTII potently and dose-dependently increased the PTEN protein levels (Figure 3A) but decreased the expression level of inactive, phosphorylated PTEN (pPTEN; Figure 3B) in B16-F10 melanoma cells.